Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04622202
Other study ID # 6408
Secondary ID
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date November 15, 2020
Est. completion date March 1, 2021

Study information

Verified date February 2021
Source Zagazig University
Contact Sara Abdel Naby, M.D
Phone 01096017090
Email sara.abdelnaby.ali@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

There is exaggerated neuroendocrine stress response to laryngoscopy and endotracheal intubation during the Induction to anesthesia-delivery (I-D) period under light anesthesia. Mechanical stimulation of laryngeal proprioceptors elicits increased secretion of cortisol and catecholamine with subsequent elevation of blood pressure from 40 to 50 % and heart rate up to 20 % during direct laryngoscopy and endotracheal intubation


Description:

The sample size was calculated using OPEN EPI program assuming that the mean visual analogue scale anxiety score was 49.3±14.1 among oral pregabalin group and was 58.6± 14.4 among Placebo group (8) so at power of study 80% confidence interval 95%, the sample size was calculated to be 74 cases (37in each group


Recruitment information / eligibility

Status Recruiting
Enrollment 74
Est. completion date March 1, 2021
Est. primary completion date February 28, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 21 Years to 38 Years
Eligibility Inclusion Criteria: - Age: 21-38 years old. - Pregnant Female with a singleton fetus of at least 36 weeks of gestation. - American Society of Anesthesiologist Physical status: 1& II. - Body Mass Index (BMI) (25-30kg/m²). - Type of operations: elective caesarean section under general anesthesia. - Written informed consent from the parturient. Exclusion Criteria: - Altered mental state. - Women with known history of allergy to pregabalin. - Women with uncontrolled diabetes mellitus, bleeding, coagulation disorders, Hepatic, renal, Cardiovascular, respiratory disease and neuropsychiatric disorders. - Patients receiving anticonvulsants, antidepressants. - Pregnancy induced hypertension, intrauterine growth restriction or fetal compromise

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Pregabalin 150mg
oral capsule pregabalin 150 mg.
multivitamin
oral placebo in the form of oral multivitamin capsule.

Locations

Country Name City State
Egypt Sara Mohamed Abdel Nabi Zagazig

Sponsors (1)

Lead Sponsor Collaborator
Zagazig University

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary preoperative maternal anxiety changes Anxiety by State-Trait Anxiety Inventory (STAI) questionnaire before drug administration and 60 minutes after giving drug (pre-induction). change from baseline at 60 minutes after giving drug preoperative.
Secondary Number of participant with changes in level of consciousness changes in level of consciousness of participant by Alert, verbal response, pain response and unresponsive (AVPU) scale 60 minutes after giving drug (pre-induction).
Alert: The patient is aware of the examiner and can respond to the environment around them on their own. The patient can also follow commands, open their eyes spontaneously, and track objects.
Verbally Responsive: The patient's eyes do not open spontaneously. The patient's eyes open only in response to a verbal stimulus directed toward them. The patient is able to react to that verbal stimulus directly and in a meaningful way.
Painfully Responsive: The patient's eyes do not open spontaneously. The patient will only respond to the application of painful stimuli by an examiner. The patient may move, moan, or cry out directly in response to the painful stimuli.
Unresponsive: The patient does not respond spontaneously. The patient does not respond to verbal or painful stimuli.
at 60 minutes preoperative
Secondary Heart rate Heart rate will be recorded preoperative baseline, 0 (at intubation) 1, 3, 5, 10 and 15 minutes after intubation. at baseline, 0 (at intubation) 1, 3, 5, 10 and 15 minutes after intubation.
Secondary mean arterial blood pressure mean arterial blood pressure at baseline, 0 (at intubation) 1, 3, 5, 10 and 15 minutes after intubation.
Secondary Serum glucose Serum glucose level will be recorded preoperative and at 10 minutes after intubation. preoperative and at 10 minutes after intubation.
Secondary cortisol level cortisol level will be recorded preoperative and at 10 minutes after intubation. preoperative and at 10 minutes after intubation.
Secondary Baby Apgar score Apgar score at 1 and 5 min after delivery Apgar Scoring
Apgar Sign 2 1 0 Appearance (skin color) Normal color all over (hands and feet are pink) Normal color (but hands and feet are bluish) Bluish-gray or pale all over Pulse (heart rate) Normal (above 100 beats per minute) Below 100 beats per minute Absent (no pulse) Grimace ("reflex irritability") Pulls away, sneezes, coughs, or cries with stimulation Facial movement only (grimace) with stimulation Absent (no response to stimulation) Activity (muscle tone) Active, spontaneous movement Arms and legs flexed with little movement No movement, "floppy" tone Respiration (breathing rate and effort) Normal rate and effort, good cry Slow or irregular breathing, weak cry Absent (no breathing)
A baby who scores a 7 or above on the test is considered in good health.
at 1 and 5 minutes after delivery
See also
  Status Clinical Trial Phase
Recruiting NCT03399019 - Bispectral Index(BIS) on Depth of Sedation With Dexmedetomidine, Propofol and Midazolam During Spinal Anesthesia N/A
Completed NCT03220880 - Intranasal Dexmedetomidine Sedation in Children for Non-painful Procedures
Recruiting NCT04820205 - Comparison of Oral Chloral Hydrate and Combination of Intranasal Dexmedetomidine and Ketamine for Procedural Sedation in Children N/A
Recruiting NCT04549623 - End-Tidal Carbon Dioxide Monitoring Device for Sedation During Endoscopic Ultrasonography N/A
Recruiting NCT04822064 - Comparison of Oral Chloral Hydrate and Combination of Intranasal Dexmedetomidine and Ketamine for Rescue After Failed Pediatric Procedural Sedation N/A
Completed NCT01001533 - Assess the Ability of Electrical Cardiometry to Trend Hemodynamic Variables During Dexmedetomidine Sedation N/A
Completed NCT01527903 - A Comparison Between Propofol-Remifentanil and Midazolam-Remifentanil Sedation in the Intensive Care Unit Phase 4
Completed NCT00747721 - Pharmacokinetics of Dexmedetomidine During Prolonged Infusion in ICU Phase 1
Completed NCT00158873 - Pharmaco-Economic Study Of Ultiva In Intensive Care Unit(ICU)Subjects Phase 4
Terminated NCT00205517 - Sedation and Psychopharmacology in Critical Care N/A
Recruiting NCT04096768 - The Use of Ketamine and Dexmedetomidine in Intensive Care Sedation Phase 3
Active, not recruiting NCT05082623 - The Effect of Music on Delirium, Pain, Need of Sedation, Anxiety and Vital Parameters N/A
Suspended NCT03285165 - Cerebral Vascular Effects of Dexmedetomidine Versus Propofol Sedation in Intubated Mechanically Ventilated ICU Patients Phase 2/Phase 3
Active, not recruiting NCT04788589 - Sedation and Ventilator Weaning Protocol in PICU N/A
Completed NCT03425474 - Study of Remimazolam Tosilate in Patients Undergoing Diagnostic Upper GI Endoscopy Phase 3
Recruiting NCT06061159 - The ED95 of Single Intravenous Bolus Remimazolam Besylate in Pediatric Patients During General Anesthesia Induction Phase 4
Completed NCT06449365 - Comparison of Intravenous V/S Nasal Atomizer Delivery of Midazolam for Conscious Sedation for No-scalpel Vasectomy Phase 4
Completed NCT02171910 - Doxapram as an Additive to Propofol Sedation in Sedation for ERCP Phase 4
Completed NCT02211118 - Sedation and Physiological Effects of Intranasal Dexmedetomidine in Severe COPD Phase 4
Completed NCT01694745 - EUROpean Pain Audit In Neonates N/A